Most-Upgraded StocksMost-UpgradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $80.95 +0.05 (+0.06%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Edwards Lifesciences Stock (NYSE:EW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$80.02▼$81.1250-Day Range$73.79▼$81.7652-Week Range$64.00▼$83.00Volume1.74 million shsAverage Volume4.49 million shsMarket Capitalization$47.53 billionP/E Ratio11.65Dividend YieldN/APrice Target$85.90Consensus RatingModerate Buy Company Overview Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreEW MarketRank™: Edwards Lifesciences scored higher than 88% of companies evaluated by MarketBeat, and ranked 135th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 12 buy ratings, 10 hold ratings, and 1 sell rating.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.24% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.24% in the coming year, from $2.45 to $2.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 11.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 11.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.76.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.39% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 15.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-0.95 Percentage of Shares Shorted1.39% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 15.77%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.45 News SentimentEdwards Lifesciences has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Edwards Lifesciences this week, compared to 25 articles on an average week.Search InterestOnly 6 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows5 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,897,762.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesEdwards Lifesciences Corporation (NYSE:EW) VP Daniel J. Lippis Sells 4,114 SharesJuly 29, 2025 | insidertrades.comEdwards Lifesciences: Strategic Positioning and Growth Potential Drive Buy Rating Amid TAVR Market ExpansionAugust 28 at 4:51 AM | tipranks.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 28 at 2:00 AM | Brownstone Research (Ad)Insider Action: Major Stock Sale at Edwards Lifesciences!August 25 at 10:10 PM | tipranks.comResearch Analysts Set Expectations for EW FY2026 EarningsAugust 22, 2025 | americanbankingnews.comEdwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 22, 2025 | americanbankingnews.comEdwards Lifesciences: A Market Leader Stuck In 'Hold' Mode Despite Solid GrowthAugust 20, 2025 | seekingalpha.comEdwards Lifesciences Corporation (EW) Announces Accelerated Share Repurchase AgreementAugust 19, 2025 | gurufocus.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $74.03 at the start of the year. Since then, EW stock has increased by 9.2% and is now trading at $80.8150. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) announced its quarterly earnings data on Thursday, July, 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The business's revenue was up 11.9% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were payable to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include these companies: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include Vanguard Group Inc. (11.92%), State Street Corp (4.37%), Bank of New York Mellon Corp (3.00%) and Geode Capital Management LLC (2.17%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Donald E Bobo Jr, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Daniel J Lippis, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Last Earnings7/24/2025Today8/28/2025Next Earnings (Estimated)10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees15,800Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$85.90 High Price Target$100.00 Low Price Target$60.00 Potential Upside/Downside+7.0%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$6.95 Trailing P/E Ratio11.56 Forward P/E Ratio32.78 P/E Growth3.92Net Income$4.17 billion Net Margins72.96% Pretax Margin28.62% Return on Equity15.01% Return on Assets11.56% Debt Debt-to-Equity Ratio0.06 Current Ratio4.68 Quick Ratio3.87 Sales & Book Value Annual Sales$5.44 billion Price / Sales8.67 Cash Flow$2.70 per share Price / Cash Flow29.76 Book Value$18.07 per share Price / Book4.44Miscellaneous Outstanding Shares587,100,000Free Float579,526,000Market Cap$47.14 billion OptionableOptionable Beta1.08 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:EW) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.